Alphatec (NASDAQ:ATEC) Upgraded by Wall Street Zen to Buy Rating

Alphatec (NASDAQ:ATEC) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

Other research analysts also recently issued research reports about the company. Barclays reiterated an “overweight” rating and set a $22.00 price target (up previously from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Wells Fargo & Company increased their price target on Alphatec from $14.00 to $16.00 and gave the stock an “overweight” rating in a research note on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alphatec in a research note on Tuesday. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $20.00 price target on shares of Alphatec in a research note on Friday, August 1st. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Alphatec presently has an average rating of “Moderate Buy” and a consensus target price of $18.14.

Alphatec Trading Up 4.4%

Shares of Alphatec stock opened at $14.89 on Friday. Alphatec has a 1 year low of $5.08 and a 1 year high of $16.70. The firm has a market cap of $2.20 billion, a PE ratio of -13.18 and a beta of 1.05. The stock has a fifty day moving average price of $15.16 and a 200-day moving average price of $12.78. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.08. The business had revenue of $185.54 million for the quarter, compared to analysts’ expectations of $178.85 million. During the same period in the prior year, the business earned ($0.29) earnings per share. The company’s revenue for the quarter was up 27.5% compared to the same quarter last year. Alphatec has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Alphatec will post -1.08 EPS for the current year.

Insiders Place Their Bets

In other Alphatec news, EVP Craig E. Hunsaker sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $15.00, for a total value of $750,000.00. Following the completion of the transaction, the executive vice president owned 1,400,018 shares in the company, valued at $21,000,270. This trade represents a 3.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Patrick Miles sold 300,000 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $15.73, for a total value of $4,719,000.00. Following the completion of the transaction, the chief executive officer owned 5,564,078 shares of the company’s stock, valued at approximately $87,522,946.94. This represents a 5.12% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 780,575 shares of company stock worth $11,769,527 over the last quarter. Insiders own 20.90% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ATEC. GAMMA Investing LLC boosted its stake in Alphatec by 38,433.3% in the 1st quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company’s stock worth $228,000 after purchasing an additional 2,306 shares during the period. SG Americas Securities LLC boosted its position in shares of Alphatec by 28.3% during the 1st quarter. SG Americas Securities LLC now owns 56,927 shares of the medical technology company’s stock valued at $577,000 after acquiring an additional 12,553 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of Alphatec by 301.0% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 59,987 shares of the medical technology company’s stock valued at $608,000 after acquiring an additional 45,027 shares during the last quarter. Segment Wealth Management LLC bought a new stake in shares of Alphatec during the 1st quarter valued at about $101,000. Finally, Oppenheimer Asset Management Inc. boosted its position in shares of Alphatec by 13.4% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 13,144 shares of the medical technology company’s stock valued at $133,000 after acquiring an additional 1,552 shares during the last quarter. Institutional investors own 66.35% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.